Evidence map›Paper›PMID 38472493›Full record

Trial reportScientific reports2024

Discussing the safety and effectiveness of transcatheter arterial embolization combined with intravenous chemotherapy in treating locally advanced breast cancer.

Jingjun Zhang, Jie Zhang, Xiangke Niu, Yongxiang Zhou, Yufeng Guo, Yuanzhi Wang, Feng Shou

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jingjun ZhangJianyang People's Hospital, Jianyang City, 641400, Sichuan Province, China.
Jie ZhangThe First Affiliated Hospital of Chengdu Medical College, Chengdu City, Sichuan Province, China.
Xiangke NiuAffiliated Hospital of Chengdu University, Chengdu City, Sichuan Province, China.
Yongxiang ZhouJianyang People's Hospital, Jianyang City, 641400, Sichuan Province, China.
Yufeng GuoJianyang People's Hospital, Jianyang City, 641400, Sichuan Province, China.
Yuanzhi WangJianyang People's Hospital, Jianyang City, 641400, Sichuan Province, China.
Feng ShouJianyang People's Hospital, Jianyang City, 641400, Sichuan Province, China. shou_feng2004@163.com.
Fuyang City People's Hospital · CNChengdu University · CNFirst Affiliated Hospital of Chengdu Medical College · CN

Funding

Beijing Medical Award Foundation YXJL-2020-0972-0423
6 · The paper itself

Abstract

To investigate the efficacy and safety of drug-eluting bead-transarterial chemoembolization (DEB-TACE) combined with systemic chemotherapy in HR+/Her2- locally advanced breast cancer (LABC) patients. A controlled study was conducted on LABC patients treated at Jianyang People's Hospital and the First Affiliated Hospital of Chengdu Medical College from December 2020 to June 2022. The patients were randomly divided into the experimental group and the control group. The experimental group received DEB-TACE combined with the TAC regimen (175 mg/m

Indexed as

Breast NeoplasmsCarcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsChinaDoxorubicinFemaleHumansTreatment OutcomeDoxorubicinDrug-eluting beadsLocally advanced breast cancer (LABC)Neoadjuvant chemotherapySafety evaluation

Identifiers

PMID38472493
PMCPMC10933325
OpenAlexW4392886236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.